Congenica, a Cambridge, UK-based provider of clinical genome analysis technology, raised £8m ($10m) in Series B funding.
Backers included existing investors Cambridge Innovation Capital and Amadeus Capital Partners and new investor Parkwalk Advisors. Following its investment, Alastair Kilgour at Parkwalk will join Congenica’s Board.
The company intends to use the funds to sustain the commercial roll out of its Sapientia clinical genome analysis platform, by accelerating international growth and expanding customer support. It will also invest in further product development and innovation.
Led by CEO Tom Weaver, COO Dr Martin Dougherty, and Chief Business Officer Dr Shikha O’Brien, Congenica has developed the Sapientia technology platform to analyze genome-scale DNA data, producing comprehensive diagnostic reports that facilitate clinical decision-making and inform R&D.
Since the launch in 2014, the technology has been adopted across the UK, China, US and other EU countries and has been validated by independent institutes and clinicians including Genomics England Ltd under the UK 100K Genomes Project.